AMAG Spends $700 Million To Better Sell Makena

Purchase of Cord Blood Registry is expected to boost commercialization of preterm birth drug Makena, while adding a stable growth business to AMAG and offering cost synergies.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America